GraftWorx: Bel Air medical device firm raises $1.9 million to advance work on smart stents

Bel Air medical device company GraftWorx has raised $1.9 million to back pre-clinical trials of its smart stents that can detect impending artery blockages to avoid costly and risky complications. The seed round includes $500,00 from Maryland Venture Fund, $200,000 from BioMaryland Center and $100,000 from TEDCO. GraftWorx is developing a new approach to treating peripheral artery disease, which is when plaque builds up along artery walls and restricts blood flow. A stent or prosthetic graft can...

Read full article »

Top Competitors or Alternatives

Looks like nobody has added any competitors for GraftWorx yet.

Missing a competitor? Contribute!

Est. Annual Revenue
Est. Employees
David J.Kuraguntla's photo - Founder & CEO of GraftWorx

Founder & CEO

David J.Kuraguntla

CEO Approval Rating


GraftWorx is an early-stage medical device with innovation solution in the treatment of peripheral arterial disease. Read more